XIMARACT

This brand name is authorized in Austria, Estonia, Lithuania, Netherlands, Poland, Spain.

Active ingredients

The drug XIMARACT contains one active pharmaceutical ingredient (API):

1
UNII R8A7M9MY61 - CEFUROXIME SODIUM
 

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
 
Read more about Cefuroxime

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
S01AA27 S Sensory organs → S01 Ophthalmologicals → S01A Antiinfectives → S01AA Antibiotics
Discover more medicines within S01AA27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1682434, 1682456, 1682467
ES Centro de información online de medicamentos de la AEMPS 81381
LT Valstybinė vaistų kontrolės tarnyba 1076127, 1081200, 1081201
NL Z-Index G-Standaard, PRK 103608
PL Rejestru Produktów Leczniczych 100315700

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈